A family of arginal thrombin inhibitors related to efegatran.
Three new tripeptide arginal thrombin inhibitors were shown to have potent anticoagulant and antithrombotic activity: D-MePhg-Pro-Arg-H (LY287045), D-1-Tiq-Pro-Arg-H (LY294291), and D-MePhe-Pro-Arg-H (Efegatran). Efegatran and the related arginals differ mechanistically from old and from new anticoagulant agents. As illustrated with x-ray diffraction analysis of crystals of the LY294291 complex with human thrombin, the family of arginals binds thrombin with the P3, P2, and P1 residues interacting with the putative S3, S2, and S1 fibrinogen-binding sites. A hemi-acetal bond at Ser 195 was shown to contribute to the tight-binding reversible competitive thrombin inhibition properties observed with the arginal family. Tight-binding Kass values from thrombin inhibition studies correlated with thrombin clottin inhibition potency. The thrombin time (TT) assay was prolonged twofold with 33 nM Efegatran, which demonstrated an apparent Kass value of 0.8 x 10(8) L/mol (for comparison, 17 nM hirudin was required to prolong the TT assay two-fold). There are empirical anticoagulant selectivity differences between Efegatran and hirudin, manifested by large activated partial thromboplastin time (aPTT)/TT effect ratios (30 to 55) found with the arginals, as compared to the small aPTT/TT effect ratio (2 to 3) found with hirudin. The underlying anticoagulant mechanism differences between the arginals and hirudin appear to be confined to the aPTT pathway and, therefore, might involve different effects toward thrombin feedback activation of factor VIII. The arginals did not substantially inhibit other coagulation factor serine proteases. Antithrombotic effects of Efegatran and the arginal family occur at low infusion doses in dogs and appear to correlate with effects on TT without requiring perturbation of the aPTT. Selectivity properties regarding the fibrinolytic enzymes were shown to be important for successful use of the arginals in vivo as adjunctive agents during tissue plasminogen activator (t-PA) thrombolysis. The data suggest that LY287045, LY294291, and Efegatran should be expected to be useful as antithrombotic adjuncts to thrombolytic therapy with t-PA, urokinase, or streptokinase and should be expected to spare endogenous fibrinolysis. Efegatran has been evaluated in phase I clinical studies and is currently under clinical investigation in phase II protocols as a new cardiovascular anticoagulant.
Smith
G F
GF
Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, Indiana 46285, USA.
Shuman
R T
RT
Craft
T J
TJ
Gifford
D S
DS
Kurz
K D
KD
Jones
N D
ND
Chirgadze
N
N
Hermann
R B
RB
Coffman
W J
WJ
Sandusky
G E
GE
Roberts
E
E
Jackson
C V
CV
D000818:Animals; D000991:Antithrombins / Q000378:metabolism* / Q000494:pharmacology; D018360:Crystallography, X-Ray; D004151:Dipeptides / Q000378:metabolism* / Q000494:pharmacology; D004285:Dogs; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D009842:Oligopeptides / Q000378:metabolism* / Q000494:pharmacology; D011487:Protein Conformation; D018179:Receptors, Thrombin / Q000037:antagonists & inhibitors / Q000378:metabolism
D000991:Antithrombins; D004151:Dipeptides; C103552:LY 287045; C103553:LY 294291; D009842:Oligopeptides; D018179:Receptors, Thrombin; C064289:efegatran